For example, in NSCLC, ILT4 overexpression suppresses the tumor immunity by impairing T cell response and recruiting M2-like TAMs, preventing immunosuppression and enhancing the efficacy of PD-L1 inhibitor in EGFR wild-type NSCLC [9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.